Bevacizumab in recurrent high-grade pediatric gliomas

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promise in treating recurrent adult high-grade glioma (HGG). However, there is very little data on recurrent or progressive pediatric HGG treated with bevacizumab. We report the results of a single institution experience using bevacizumab and irinotecan in children who relapsed or progressed following standard therapy. Twelve pediatric patients with recurrent or progressive HGG received bevacizumab at 10 mg/kg every 2 weeks with irinotecan at 125 mg/m(2). Magnetic resonance imaging (MRI) was performed prior to therapy and every 8 weeks subsequently. Ten patients had supratentorial HGG; 2 had DIPG. Radiological responses were defined according to MacDonald's criteria. Progression-free survival (PFS), overall survival (OS), and toxicities were analyzed. Ten (83.3%) patients tolerated bevacizumab without serious toxicity. Therapy was discontinued in 1 patient because of anaphylaxis. Another patient developed grade III delayed wound healing and deep vein thrombosis. Two patients (16.7%) experienced a partial response after the first MRI. No complete radiographic responses were seen. Stable disease was noted in 4 (33.3%) patients. The median PFS and OS were 2.25 and 6.25 months, respectively. A diffuse invasive recurrence pattern was noted in 5 (45.5%) patients. Treatment tolerance, toxicity, and recurrence profiles were comparable to adult HGG patients treated with bevacizumab. However, the radiological response rate, response duration, and survival appeared inferior in pediatric patients. Genetic differences in pediatric gliomas might account for this difference.

Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models

“…Bevacizumab has been studied in a number of nonrandomized trials in pediatric brain tumor patients. Efficacy in these trials has been variable, with a subset of patients showing clear radiological and/or clinical improvement (13,14). The role of bevacizumab in the treatment of patients with DIPG is even less clear but is currently studied in several trials (refs.…”

Pediatric Glioblastoma

“…Most studies indicate that TMZ chemotherapy does not affect survival figures in children, although a recent study has shown otherwise. A trial similar to the Stupp trial involving the pediatric patients did not show any benefit of TMZ in children (61). MGMT promoter methylation, whenever present, potentiates the activity of TMZ even in children.…”

Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience

“…26,27 Other monoclonal antibodies such as bevacizumab, an anti-VEGF molecule, have been used in the treatment of children with brain tumors at significantly lower cumulative doses. [28][29][30][31] Children were administered bevacizumab at 10 or 15 mg/kg every 2 or 3 weeks as long as they did not show unacceptable toxicity or disease progression. In general, toxicities reported for bevacizumab were grade 1-2 hypertension, proteinuria, lymphopenia, wound healing delay, grade 1 to 3 fatigue, grade 1 central nervous system (CNS) hemorrhage and grade 4 CNS ischemia.…”